Evidence map›Paper›PMID 37336266›Full record

Trial reportOphthalmology. Glaucoma

Risk Calculation in the Medication Arm of the Ocular Hypertension Treatment Study.

Ari Leshno, Carlos Gustavo De Moraes, George A Cioffi, Michael Kass, Mae Gordon, Jeffrey M Liebmann

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Ophthalmology. Glaucoma. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Ari LeshnoBernard and Shirlee Brown Glaucoma Research Laboratory, Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Irving Medical Center, New York, New York; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Carlos Gustavo De MoraesBernard and Shirlee Brown Glaucoma Research Laboratory, Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Irving Medical Center, New York, New York.
George A CioffiBernard and Shirlee Brown Glaucoma Research Laboratory, Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Irving Medical Center, New York, New York.
Michael KassDepartment of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri.
Mae GordonDepartment of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri.
Jeffrey M LiebmannBernard and Shirlee Brown Glaucoma Research Laboratory, Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Irving Medical Center, New York, New York. Electronic address: jeffrey.liebmann@columbia.edu.
Columbia University · USColumbia University Irving Medical Center · USTel Aviv University · IL

Funding

OHTS DATA COORDINATIONU10EY009341 · NEI · WASHINGTON UNIVERSITY · PI GORDON, MAE O · 1992 to 2009
$12.3M
EGPS/OHTS Collaborative AnalysisR03EY015498 · NEI · WASHINGTON UNIVERSITY · PI GORDON, MAE O · 2004 to 2005
$393k
NEI NIH HHS R03 EY015498NEI NIH HHS U10 EY009341
6 · The paper itself

Abstract

purposeRisk assessment is integral to the management of individuals with ocular hypertension (OHTN). This study aims to determine the predictive accuracy of the Ocular Hypertension Treatment Study 5-year risk calculator (OHTS calculator) among treated patients with OHTN by applying it to patients randomized to the Ocular Hypertension Treatment Study (OHTS) medication arm.

designPost hoc secondary analysis of a randomized clinical trial. SUBJECTS: Individuals participating in the OHTS who were randomized to the medication arm. Only participants with complete baseline data in both eyes were included (n = 726).

methodsThe hazard ratios (HRs) of the medication group in OHTS were compared to the HR used for the OHTS calculator using the z-test statistic to establish the OHTS calculator's generalizability to the OHTS medication arm. The performance of the OHTS calculator among the OHTS medication group was evaluated twice, using both untreated baseline intraocular pressure (IOP) and average treated IOP during the first 24 months for the IOP variable.

main outcome measuresThe performance was determined based on the model's accuracy in estimating the risk of reaching an OHTS primary open-angle glaucoma (POAG) end point using calibration chi-square and discriminating between participants who did or did not develop POAG.

resultsThe HRs for the OHTS medication arm were not significantly different from those used in the OHTS calculator for untreated OHTN derived from observation arm data (P > 0.1). Based on the calibration chi-square test for the medication group, the OHTS calculator prediction model had good predictive accuracy when using the mean treated IOP and poorer predictive accuracy with the untreated baseline IOP (chi-square 10 and 29, respectively). The model had good discrimination with treated IOP (c-statistic = 0.77), comparable to what has been reported for the OHTS calculator in the OHTS observation group.

conclusionsThe OHTS calculator can be applied to treated patients with OHTN, and repeat risk calculation after initiating IOP reduction may provide useful information that can aid in disease management. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Indexed as

GlaucomaGlaucoma, Open-AngleOcular HypertensionHumansIntraocular PressureTonometry, OcularGlaucomaOcular hypertensionPrimary open-angle glaucomaProgressionTreatment

Identifiers

PMID37336266
PMCPMC10725513
OpenAlexW4381056919

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.